Indian Drug Makers Introduce New Drugs To Thwart Asthma Drug Caps
This article was originally published in PharmAsia News
Executive Summary
Major drug makers in India are producing new brands of a popular asthma drug in an effort to avoid the nation's price controls. Cipla, Dr. Reddy's, Ranbaxy and Zydus Cadila have brought out new brands based on doxopthyline, a derivative of theophyline, which is subject to controls. The move is being made even though doxopthyline is considered less effective, because the makers can fetch a higher price. Dr. Reddy's introduced its Doxobid, Macleods its Doxoril, Ranbaxy its Synasma and Zydus its Doxolin within the past year or so, none subject to price controls. (Click here for more